test

Lung Cancer

10
A Multi-arm Phase I Safety Study of Nivolumab in Combination with Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects with Stage IIIB/IV Non-small Cell Lung Cancer
Disease/Condition: Lung
Principal Investigator: Scott Gettinger
A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects With Advanced Non-Small Cell Lung Cancer
Disease/Condition: Lung
Principal Investigator: Sarah Goldberg
A Phase 1b/2 Study of OMP-59R5 in Combination with Etoposide and Cisplatin in Subjects with Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE)
Disease/Condition: Lung
Principal Investigator: Anne Chiang
A Phase I/II Study of HSP90 Inhibitor AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Disease/Condition: Lung
Principal Investigator: Scott Gettinger
A Phase I/II, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Disease/Condition: Bladder | Breast - Female | Lung | Pancreas | Stomach
Principal Investigator: Joseph Paul Eder
A Phase Ib Study of the Safety and Pharmacology of MPDL3280A Administered with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer
Disease/Condition: Lung
Principal Investigator: Scott Gettinger
A Phase II Study of MK-3475 in Patients with Metastatic Melanoma or Non-Small Cell Lung Cancer with Untreated Brain Metastases
Disease/Condition: Lung | Melanoma, skin
Principal Investigator: Harriet Kluger
A Phase II Study of Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib for Patients with EGFR Mutation Who Have Previously Progressed on an EGFR Tyrosine Kinase Inhibitor (TKI)
Disease/Condition: Lung
Principal Investigator: Roy Decker
A Phase II, Multicenter, Single-Arm Study OF MPDL3280A in Patients with PD-L1−Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Disease/Condition: Lung
Principal Investigator: Scott Gettinger
A Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
Disease/Condition: Lung
Principal Investigator: Roy Herbst
A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer
Disease/Condition: Lung
Principal Investigator: Roy Herbst
A Phase IIb, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma
Disease/Condition: Lung
Principal Investigator: Sarah Goldberg
Phase 1b/2, Multicenter, Open-label Study of Carfilzomib, Carboplatin, and Etoposide in Subjects with Previously Untreated Extensive-stage Small-cell Lung Cancer
Disease/Condition: Lung
Principal Investigator: Anne Chiang
Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive (AURA2)
Disease/Condition: Lung
Principal Investigator: Sarah Goldberg